Verastem Posts $25.1M Q2 Revenue, Secures $90M Non-Dilutive Funding, Advances KRAS G12D Program
VSTM sits 92% above its 52-week low of $3.43.
Summary
Verastem reported Q2 2026 net product revenue of $25.1 million for its AVMAPKI FAKZYNJA CO-PACK, up from $18.7 million in Q1, showing strong commercial traction. The company also secured $90 million in non-dilutive funding, strengthening its balance sheet ahead of key data readouts. On the pipeline front, VS-7375, its oral KRAS G12D inhibitor, has dosed first patients in three registration-directed Phase 2 trials for pancreatic, colorectal, and non-small cell lung cancers, with enrollment expected to complete by year-end. Updated RAMP 201 Japan data showed a 44% overall response rate and 94% disease control rate in recurrent low-grade serous ovarian cancer. Additional clinical data for VS-7375 is expected in October. This follows the June 17 positive RAMP 205 data and the June 23 VS-7375 preliminary data, reinforcing a pattern of advancing clinical milestones. The revenue growth and non-dilutive funding address the going concern risk flagged in the last 10-Q, providing a clearer runway.
At the time of this announcement, VSTM was trading at $6.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $519.3M. The 52-week trading range was $3.43 to $11.25. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.